Neurava is developing novel and innovative wearable devices for the estimated 3.5 million Americans and 65 million people worldwide with epilepsy to mitigate the risk of SUDEP, or Sudden Unexpected Death in Epilepsy. According to the CDC, each year, there are ~1.16 cases of SUDEP for every 1000 people with epilepsy1, leading to 101,000 years of potential life lost annually in the U.S., second only to stroke among neurological conditions2. Major risk factors include 1) uncontrolled or frequent seizures and 2) generalized convulsive seizures. SUDEP typically occurs during or immediately after a seizure and may result from breathing difficulty and abnormal heart rhythm1.

The round was led by Life Science Angels and included a second strategic investment from UCB, in addition to strong support from Purdue Innovates, Elevate Ventures, Rivermount Ventures, and First Leaf Capital.